Amyloid-related imaging abnormality edema is a known side effect of anti-amyloid monoclonal antibody treatments, such as Leqembi and donanemab Kisunla.
The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR.
Cardiologists and other physicians have always believed cardiac transthyretin amyloidosis, a progressive heart condition associated with a high mortality rate, was irreversible. Now, though, new evidence suggests that there may be hope.
Motives for the hesitancy are several—transportation concerns, informational inadequacies, historical wrongs—but effective resolutions can be quite simple.
Cedars-Sinai researchers are developing a deep-learning algorithm to personalize patient cardiac risk predictions in a patient-friendly, graphical report.
Someday, getting an MRI exam could be as simple as having food delivered to your door—at least that is the hope of a group of experts at the University of Minnesota who are working on a compact system said to be small enough to sit in the bed of a truck.
